Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

The 3 Best Biotech Stocks To Buy Now

By MarketBeat.com (Sean Sechler )Stock MarketsJun 09, 2021 08:28AM ET
www.investing.com/analysis/the-3-best-biotech-stocks-to-buy-now-200585074
The 3 Best Biotech Stocks To Buy Now
By MarketBeat.com (Sean Sechler )   |  Jun 09, 2021 08:28AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Some traders believe that looking at the performance of biotech stocks is one of the best ways to judge what type of market we are in. When we see money flowing into that sector, it tells us that institutional investors are in “risk-on” mode, since biotech stocks are notorious for their volatility. That’s why it's nice to see some money start to flow back into biotech stocks this week, as the sector got a big boost from Biogen (NASDAQ:BIIB)’s news that the FDA has approved the company’s Alzheimer’s drug. While we don’t know if this is the start of a new trend for the sector, there are still plenty of great reasons to be looking at biotech for opportunities at this time.

Many of the top biotech stocks have been facing selling pressure over the last few months, which means that their valuations are currently depressed. There are also several companies that have potentially huge catalysts coming up that could really help the sector get back to its best. While adding significant exposure to biotech stocks is not recommended for risk-averse investors, it’s arguably one of the more intriguing sectors of the market to look at right now based on a risk-to-reward basis. Let’s take a look at 3 of the best biotech stocks to buy now.

1. Bristol-Meyers Squibb

Biotech companies can range from extremely speculative small-cap companies to established large-cap giants with reliable sales and impressive pipelines. Bristol-Meyers Squibb falls under the latter category, which is why it's one of the best biotech stocks to consider adding at this time. As a global biopharmaceutical firm offering a broad array of conventional prescription drugs and advanced biologic treatments, it’s a company that offers a nice combination of upside potential and consistent earnings, which is certainly attractive in such a volatile sector.

With top cancer drugs such as Revlimid, Opdivo, and Yervoy, it’s clear that this company has developed a strong portfolio of drugs that can help to support the stock’s 3.03% dividend yield. There’s also a catalyst to look out for later this summer, as the FDA is expected to decide on using Opdivo as adjuvant therapy in patients with muscle-invasive urothelial carcinoma in September. This decision is big as it can lead to more sales if Opdivo is able to help people with different cancer indications. If you are interested in a biotech stock with a strong pipeline, a history of savvy acquisitions, and an attractive dividend payout, look no further than Bristol-Meyers Squibb.

2. Vertex Pharmaceuticals

For a reminder of the risks associated with biotech investing, take a look at what happened to Vertex Pharmaceuticals (NASDAQ:VRTX) last October, when the company discontinued the development of a promising drug. The stock lost billions in market cap that month, but has since stabilized and could be a great buying opportunity at this time. Vertex is a biotechnology company that is focused on developing and commercializing therapies for the treatment of cystic fibrosis. The company has limited competition in that space, which means Vertex can rely on steady sales from its franchises of cystic fibrosis drugs for years to come. The company’s market opportunity is roughly 90% of the cystic fibrosis population, which confirms just how dominant of a position Vertex has created in cystic fibrosis treatments.

In Q1, the company reported strong earnings including product revenues of $1.72 billion, up 14% year-over-year. Vertex is also advancing clinical programs in six additional diseases beyond cystic fibrosis. Those could end up becoming growth drivers in the long term should they lead to promising results in areas like AAT deficiency and sickle cell disease. The FDA is also expected to rule on whether or not it will allow Vertex to use its drug Trikafta in children with cystic fibrosis ages 6 through 11 with certain mutations. This could be a positive catalyst for the stock and lead to more sales for the company, so keep an eye out for the ruling.

3. Johnson & Johnson

Finally, we have Johnson & Johnson (NYSE:JNJ), which is certainly one of the lowest-volatility biotech stocks out there. Johnson & Johnson is a global leader in the pharmaceutical, medical device, and consumer health care products industries and is worth adding for a few different reasons. First, the company’s pharmaceutical segment has some nice prospects in its pipeline, including 14 novel drug launches expected by the end of 2023. There’s also the fact that elective procedures should be on the uptick as the pandemic winds down, which will benefit the company’s medical devices segment.

Perhaps the best reason to add shares of Johnson & Johnson is due to the company’s incredible consistency with its dividend. Johnson & Johnson has delivered 57 consecutive years of dividend growth and is a great company to own for the long haul if you are interested in adding extra income to your portfolio. The stock currently offers a 2.57% dividend yield and is a fine choice for the more conservative biotech investors out there.

Original Post

The 3 Best Biotech Stocks To Buy Now
 

Related Articles

Tim Knight
Retailers Hitting Resistence By Tim Knight - May 26, 2022

I am taking advantage of the rush to buy stocks again by shorting some retailers that are approaching major resistance levels. Advance Auto Parts Inc (NYSE:AAP): Burlington Stores...

The 3 Best Biotech Stocks To Buy Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Billy Colgan
Billy Colgan Jun 11, 2021 2:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vertex really?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email